Abstract: An anti-CLEC12A polypeptide generally includes an amino acid sequence having at least 90% amino acid similarity to SEQ ID NO:14. In some embodiments, anti-CLEC12A polypeptide may be incorporated into an anti-CLEC12A biologic. In some of these embodiments, the anti-CLEC12A biologic can be a bi-specific Killer engager molecule (BiKE), a tri-specific Killer engager molecule (TriKE), a tetra-specific Killer engager molecule (TetraKE), a penta-specific Killer engager molecule (PentaKE), a bi-specific T cell engager molecule (BiTE), a tri-specific T cell engager molecule (TriTE), tetra-specific T cell engager molecule (TetraTE), a penta-specific T cell engager molecule (PentaTE), a chimeric antigen receptor, a full antibody, an antibody-drug conjugate (ADC) molecule, a targeted delivery construct, or a labeling construct.

Abstract: Multispecific B7H3 targeting compounds and methods of use thereof are provided. The multispecific compounds include bispecific targeting proteins including a B7H3 targeting domain and an immune cell engaging domain; and trispecific targeting proteins including a B7H3 targeting domain, an immune cell engaging domain and an immune cell activating domain. The methods of use include methods of inducing NK-mediates cell killing, methods of inducing NK expansion in vivo, and methods of treating cancer.

Abstract: This disclosure describes compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain. In an illustrative embodiment, the targeting domain selectively binds to an HIV antigen.

Abstract: An immunotherapy compound includes an NK cell engaging domain, an NK activating domain and a targeting domain. The targeting domain selectively binds to HER2, HERS, or the HER2/HER3 heterodimer complex and is operably linked to the NK activating domain and the NK cell engaging domain. The compound may be administered to a subject to induce NK-mediated killing of a cancer cell, to stimulate expansion of NK cells in the subject, and/or for treating cancer.

Abstract: Provided are compositions for activating NK cells to stimulate an immune response for treating cancer and other disorders. In one embodiment, the invention provides a compound comprising an NK engaging domain that binds to CD 16; an NK activating domain operably linked to the NK engaging domain; and a targeting domain that selectively binds to a target cell and is operably linked to the NK activating domain and the NK engaging domain, wherein the targeting domain binds to CLEC12A.